e6vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For
the month of December 2008
Commission File Number 000-28508
Flamel Technologies S.A.
(Translation of registrants name into English)
Parc Club du Moulin à Vent
33 avenue du Dr. Georges Levy
69693 Vénissieux Cedex France
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of
Form 20-F or Form 40-F.
Indicate by check mark whether registrant by furnishing the information contained in this Form
is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
If Yes is marked, indicate below the file number assigned to the registrant in connection
with Rule 12g3-2(b): 82-
INFORMATION FILED WITH THIS REPORT
Document Index
99.1
Press release regarding new contracts and research collaboration,
dated December 22, 2008.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
Flamel Technologies S.A. |
|
|
|
|
|
|
|
|
|
Dated:
December 22, 2008
|
|
By:
|
|
/s/ Stephen H. Willard
|
|
|
|
|
Name:
|
|
Stephen H. Willard
|
|
|
|
|
Title:
|
|
Chief Executive Officer |
|
|
EXHIBIT INDEX
|
|
|
Exhibit |
|
|
Number |
|
Description |
99.1
|
|
Press release regarding new
contracts and research collaboration, dated December 22, 2008. |
exv99w1
Exhibit 99.1
Flamel Technologies Announces New Micropump and Medusa Contracts, and
a Research Collaboration with Pfizer
LYON, France December 22, 2008 - Flamel Technologies (NASD: FLML) today announced that it has
entered into a new Micropump license agreement for a combination product with a new partner and
will begin formulation work immediately. Flamel also has entered into an additional feasibility
agreement involving its Medusa platform with an existing partner and work has commenced. Flamel
Technologies is engaged in 17 partnered projects and is working with seven of the top-twenty
pharmaceutical companies in the world, including a continuing research collaboration with Pfizer
Inc. (NYSE: PFE).
Stephen H. Willard, Flamels chief executive officer, commented, We are pleased to continue to add
new license agreements and projects for both our Micropump and Medusa platforms. We are making
significant strides with our existing agreements, but we retain our focus on adding new partnership
agreements, particularly with the worlds largest pharmaceutical companies. In this regard, I am
particularly pleased to announce our continuing work with Pfizer, the worlds largest
research-based biomedical and pharmaceutical company.
Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of
two unique polymer-based delivery technologies for medical applications. Flamels Medusa®
technology is designed to deliver controlled-release formulations of therapeutic proteins and
peptides. Micropump® is a controlled release and taste-masking technology for the oral
administration of small molecule drugs.
Contact:
Charles Marlio
Director of Strategic Planning and Investor Relations
tel: (+) 33 (0)4 7278 3434
fax: (+) 33 (0)4 7278 3435
Marlio@flamel.com
This document contains a number of matters, particularly as related to the status of various
research projects and technology platforms, that constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. The document reflects the current
view of management with respect to future events and is subject to risks and uncertainties that
could cause actual results to differ materially from those contemplated in such forward-looking
statements. These risks include risks that products in the development stage may not achieve
scientific objectives or milestones or meet stringent regulatory requirements, uncertainties
regarding market acceptance of products in development, the impact of competitive products and
pricing, and the risks associated with Flamels reliance on outside parties and key strategic
alliances. We undertake no obligation to update these forward-looking statements as a result of new
information, future events or otherwise. You should not place undue reliance on these
forward-looking statements. These and other risks are described more fully in Flamels Annual
Report on the Securities and Exchange Commission Form 20-F for the year ended December 31, 2007.